# A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

> **NCT01988961** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 103 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **BIOLOGICAL:** Golimumab

## Key facts

- **NCT ID:** NCT01988961
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2015-02
- **Final completion:** 2016-01
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2017-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01988961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01988961, "A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01988961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*